GlobeNewsWire
23 Jun 2026, 21:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADC Therapeutics' Phase 3 LOTIS-5 trial for ZYNLONTA reported 27 deaths in the treatment arm compared to nine in the immunotherapy arm. — High mortality rates in a confirmatory trial suggest severe safety concerns and significant risk of regulatory rejection or limited market uptake.
-0.90Pomerantz LLP is investigating ADC Therapeutics for potential securities fraud or unlawful business practices following the LOTIS-5 data release. — The initiation of a class-action investigation creates additional legal liability and corporate governance risk for the company.
-0.50ADC Therapeutics' stock price declined 66.56% over two trading sessions following the announcement of the LOTIS-5 topline data. — This confirms the market's immediate and severe negative valuation of the drug's clinical profile.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a class action investigation into securities fraud following poor trial data and a 66% stock price collapse.
The company is the subject of a legal investigation by Pomerantz LLP on behalf of investors.
The company is the subject of a legal investigation by Pomerantz LLP on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
